Rapid Influenza Diagnostic Tests (RIDT) Market Size - By End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

Rapid Influenza Diagnostic Tests Market Size

Rapid Influenza Diagnostic Tests (RIDT) Market was valued at around USD 1 billion in 2021 and is anticipated to witness 7% CAGR by the end of 2030. The growing adoption of novel influenza diagnostic techniques and the launch of innovative rapid influenza tests by major market players are creating lucrative opportunities for the market.
 

Similarly, the rising R&D expenditure to offer technologically advanced solutions to diagnose influenza is expected to improve these diagnostic test usage rates across the globe. Wide applications of rapid influenza diagnostic testing coupled with the increasing prevalence of influenza will fuel the rapid influenza diagnostic tests market revenue in the coming years.
 

The use of these tests for the detection of phenotypic & genotypic characterization of flu viruses has grown rapidly in recent years. Other advantages include eliminating the need for dedicated molecular space and costly capital equipment resulting in the increasing popularity of these influenza tests.
 

Rapid influenza diagnostic tests refer to tests used in the diagnosis of viral infection caused due to influenza viruses such as influenza A virus, influenza B virus, etc. Healthcare facilities use these influenza diagnostics tools to detect the disease, monitor the influenza progression, and offer optimal therapeutics. Rapid influenza diagnostic testing provides fast, precise, specific, & cost-effective diagnosis, and a broad array of these tests is available that finds application against several influenza viruses.
 

However, the lack of experienced professionals and advanced infrastructure in low-resource settings such as remote areas, rural areas, and urban slums interfere with the implementation of influenza testing in developing countries such as India, China, and Mexico among others. It is difficult to maintain access to quality health care services in remote and rural areas owing to a lack of transportation and communication.
 

Moreover, skilled technicians and experienced physicians are required for rapid influenza diagnostic tests to avoid the risk of false interpretations. Developing countries face the challenge of shortages of doctors and experienced healthcare professionals, especially in rural and remote areas. The physician-to-patient ratio in China is 1.49:1000 that is much lower as compared to the developed countries.
 

The lack of experienced professionals and advanced infrastructure in developing countries could result in increased morbidity and mortality hampering the rapid influenza diagnostic tests market growth over the forecast period.
 

The recent outbreak of COVID-19 has negatively impacted the rapid influenza diagnostic tests market growth. The increased demand for coronavirus testing has highly impacted other disease testing services including rapid influenza diagnostic tests. In 2020, the prevalence as well as the mortality rate due to COVID-19 was significant and people preferred to avoid any other treatment or diagnosis procedures at healthcare facilities.
 

The production facilities and supply chain were highly impacted owing to the high volume of COVID-19 patients & worldwide lockdown scenario. Most of the leading nations worldwide imposed a total lockdown and the total emphasis was shifted to the rise in demand for essential products & services, that hindered the manufacturing and adoption of rapid influenza diagnostic testing products.
 

However, in 2021, the technological advancements and incorporation of telemedicine in influenza infection diagnosis have augmented target disease diagnosis compliance and promoted the acceptance of rapid influenza diagnostic testing products. Also, among COVID-19 infected patients, influenza was related to an increased risk of infection and hospitalization, with a heightened risk of respiratory failure. Hence, the COVID-19 has impacted the market in the shorter run; however, the decreasing COVID-19 infection rates & patients and growing product demand is expected to drive market growth in the forthcoming period.
 

Rising prevalence of influenza is expected to propel the market growth

The increasing population with weakened immune systems suffering from target ailments has propelled the demand for rapid influenza diagnostic tests that has further boosted the market growth positively. Human influenza viruses comprising type A influenza and type B influenza, among others augment substantial disease burden. These conditions further inflict health care costs and affect the health-associated quality of life.
 

According to the World Health Organization (WHO) studies, seasonal influenza result in around 3 - 5 million cases of severe illness across the globe every year. As per the European Centre for Disease Prevention and Control, influenza infects around 10% -30% of Europe's population every year. Furthermore, as per the research data, between October 2020 and July 2021, around 1.3 million influenza specimens were tested in the U.S. This surging prevalence of influenza leads to a large number of patients opting for rapid influenza tests as a powerful tool for early diagnosis and control of influenza.
 

Owing to that there is a huge demand for rapid influenza diagnosis that helps in providing early treatment, thereby lessening the symptoms of the flu. Thus, owing to the above variables rising prevalence of influenza is anticipated to increase the demand for rapid influenza diagnostic tests that will prove beneficial for the market growth.
 

Technological advancements in rapid influenza diagnostic tests are anticipated to drive the business growth

The ongoing technological advancement in rapid influenza diagnostic tests is projected to stimulate market growth during the forecast period. These advancements in influenza A & B test that provides molecular flu results in less than 15 minutes have augmented the tests demand and success rate. The rapid influenza diagnostic tests industry players are emphasizing on R&D activities for developing technologically advanced rapid influenza diagnostic tests.
 

For instance, the Abbott has introduced the ID NOW Influenza A & B 2, a rapid diagnostic test that offers increased sensitivity essential for the precise detection of influenza A & B and allows instant & effective treatment decisions. Thus, the commercialization of such advanced influenza diagnostic tests will fuel market growth over the coming years. Advancement in rapid influenza diagnostic tests results in an enhancement in diagnosis, target disorders treatment, and medical therapies among others. Leading industry players comprising Quidel Corporation are focusing to introduce novel rapid influenza diagnostic tests in order to facilitate effective patient management.
 

For instance, the Solana Influenza A+B Assay developed by Quidel Corporation enables an accurate detection & differentiation of influenza and displays results on the touchscreen that can be saved to the instrument. Thus, owing to the aforementioned factors, the ongoing technological advancements in rapid influenza diagnostic tests are anticipated to propel the market expansion significantly. 
 

Rapid Influenza Diagnostic Tests Market Analysis

Based on end-use, the market is segmented as hospitals, diagnostics centers, research laboratories, and others. The diagnostics centers segment held a dominant market share in 2021 and was valued at more than USD 412 million owing to the rising demand and surging awareness pertaining to the benefits offered by diagnostics centers in providing precise diagnosis related to the influenza respiratory illness. The diagnostic centers are highly significant in early-stage disease diagnosis and reducing the risk of trial & error treatment.
 

Additionally, the patient history and techniques of these facilities are assisting the researchers in the advancement of influenza treatment solutions. Several nations are focusing on the building of diagnostic centers that are equipped with the highly effective required tests and skilled professionals along with medical personnel that assist in the process of identifying influenza in a patient that is showing specific symptoms or signs. This is further allowing each test to perform well and have a chance of receiving precise results.
 

Moreover, the surging influenza prevalence will significantly propel the adoption of rapid influenza diagnostic tests at diagnostic centers. Hence, diagnostic centers play a crucial role in influenza disease diagnosis.
 

U.S. dominated the North America rapid influenza diagnostic tests market in 2021 and is anticipated to expand at a notable pace to reach over USD 608 million by 2030 due to the presence of major market players, an increase in the number of people suffering from influenza virus, a respiratory illness, etc. As per the Centers for Disease Control and Prevention (CDC), between October 1, 2021 - April 16, 2022, around 4,700,000 – 7,900,000 flu illnesses were recorded in the U.S.
 

Additionally, this flu season recorded around 2,800 – 8,200 deaths in the U.S. These statistics are highlighting the increased requirement for influenza tests that incorporate the use of rapid influenza diagnostic tests efficiently. The rapid influenza diagnostic tests have become a significant and cost-effective tool for the diagnosis of complications related to influenza, thereby boosting the product demand significantly. Hence, the adoption of rapid influenza tests has been significantly surging in the country over the past few years.
 

Moreover, the presence of prominent industry players such as Abbott, Quidel Corporation, and Sekisui Diagnostics among others in the country are engaged in new product development & commercialization that facilitates market expansion in the U.S.
 

Rapid Influenza Diagnostic Tests Market Share

Some of the major market players operating in the rapid influenza diagnostic tests industry are :

• Quidel Corporation
• Abbott
• DiaSorin SpA
• Thermo Fischer Scientific Inc.
• Becton
• Dickinson and Company
• Meridian Bioscience Inc.
• FHoffmann-La Roche Ltd

These players are engaged in strategic acquisitions, mergers, collaborations, partnerships, expansions, and product launches among other strategies to maintain a competitive edge. These market players also focus on research and development activities that enables in garnering maximum market share.
 

Recent industry developments:

• In October 2018, Abbott received the U.S. FDA clearance for its ID NOW INFLUENZA A & B 2, a rapid influenza diagnostic testing instrument. This test delivers the fastest molecular detection and differentiation of influenza A and B virus. This product approval supported the company to broaden its influenza diagnostic tests portfolio and strengthen its market presence.
   
• In April 2021, DiaSorin SpA announced the acquisition of Luminex Corporation, a company engaged in the development of diagnostic solutions for infectious diseases. This acquisition was intended for expansion of its diagnostic portfolio comprising influenza diagnostic products in the U.S. This strategic move aided company in increasing its customer base and bolstered its industry presence. 
   

Rapid influenza diagnostic tests market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:

Click here to Buy Section of this Report

By End-use

• Hospitals
• Diagnostics Centers
• Research Laboratories
• Others

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE